Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcadia Biosciences, Inc.RKDA · Entity 8593 | Director · Chief Executive Officer | June 03, 2019 | June 07, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcadia Biosciences, Inc.
Report date June 03, 2019 · Filed June 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.04 · Expires 2029-06-03 | Direct | 188,150 |
Reported balance
After 2019-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-03 · Grant · Acquired 28,000 · Balance 188,150 F1: The Option vests with respect to 25% of the total securities subject to the option on the first anniversary of the date of award, or June 3, 2020, with the remaining 75% vesting in 36 equal installments beginning June 30, 2020 and ending May 31, 2023, subject to the Participant's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The Option vests with respect to 25% of the total securities subject to the option on the first anniversary of the date of award, or June 3, 2020, with the remaining 75% vesting in 36 equal installments beginning June 30, 2020 and ending May 31, 2023, subject to the Participant's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2019 Filed Jun 7, 2019 15:54 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 28,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-19-035492 · doc4.xml · derivative · entry 1 KETKAR RAJENDRA D. · CIK 0001674900 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,150 Underlying: Common Stock · 28,000 shares Expires 2029-06-03 F1 · derivative.exercise_date: The Option vests with respect to 25% of the total securities subject to the option on the first anniversary of the date of award, or June 3, 2020, with the remaining 75% vesting in 36 equal installments beginning June 30, 2020 and ending May 31, 2023, subject to the Participant's continued service. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 19:20 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (Right to Buy) · Derivative | 106,400 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001209191-18-051839 · doc4.xml · derivative · entry 1 KETKAR RAJENDRA D. · CIK 0001674900 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,150 Underlying: Common Stock · 106,400 shares Expires 2028-09-18 F1 · derivative.exercise_date: The options will vest monthly in equal installments over a period of two years from the date of the grant, subject to the Participant's continued service. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 18:01 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 325,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001209191-17-038972 · doc4.xml · derivative · entry 1 KETKAR RAJENDRA D. · CIK 0001674900 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2027-06-08 F1 · shares: 25% of the total number of shares subject to the Option will vest on the first anniversary of the date of the award; the remaining 75% will vest in 36 equal installments, subject to the Participant's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.